CARsgen Therapeutics currently has 11 product candidates, all of which were fully developed in house with global rights, covering conventional 2 nd -generation, next-generation, and allogeneic CAR-T cell therapies, indicating a comprehensive and visionary portfolio development. CARsgen Therapeutics has obtained 7 IND approvals for CAR-T therapies in China, the United States and Canada, ranking the first among all CAR-T companies in China.